On December 23, 2024, aTyr Pharma, Inc. announced an amendment to its Open Market Sale Agreement with Jefferies LLC, originally established in April 2022. The amendment, titled Amendment No. 1, increases the aggregate offering amount under the agreement, enabling the company to issue and sell additional shares of common stock. These sales, conducted at-the-market under applicable SEC rules, will be made pursuant to the company's effective registration statement and supplemented by a prospectus filed on the same date.

While Jefferies is tasked with facilitating these sales based on company instructions, aTyr Pharma is under no obligation to sell any shares under the amended agreement. Cooley LLP provided a legal opinion on the validity of the additional shares, included as part of the company's filing.